295 related articles for article (PubMed ID: 7878824)
1. High-dose cyclosporine A induction therapy in liver transplant recipients with normal postoperative renal function: a prospective study.
Cherqui D; Duvoux C; Salvat A; Lauzet JY; Metreau JM; Julien M; Fagniez PL; Dhumeaux D
Transplant Proc; 1995 Feb; 27(1):1134-5. PubMed ID: 7878824
[No Abstract] [Full Text] [Related]
2. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
[No Abstract] [Full Text] [Related]
3. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
[No Abstract] [Full Text] [Related]
4. Correlation between Banff classification, acute renal rejection scores, and reversal of rejection.
Gaber LW; Moore LW; Alloway RR; Flax S; Gaber AO
Transplant Proc; 1995 Feb; 27(1):1019. PubMed ID: 7878784
[No Abstract] [Full Text] [Related]
5. A double-blind randomized study of Sandimmun Neoral versus Sandimmun in new renal transplant recipients: results after 12 months. The International Sandimmun Neoral Study Group.
Niese D
Transplant Proc; 1995 Apr; 27(2):1849-56. PubMed ID: 7725531
[No Abstract] [Full Text] [Related]
6. Incidence and patterns of rejection using different induction therapies in liver transplant recipients.
Elkashab M; Reizig M; Greig PD; Cameron R; Phillips MJ; Chung S; Cattral M; Levy G
Transplant Proc; 1994 Oct; 26(5):2669-71. PubMed ID: 7940835
[No Abstract] [Full Text] [Related]
7. Late acute rejection in renal transplant recipients: response to steroid treatment.
Prieto C; Pulido F; Rodríguez-Paternina E; Algranati C; Bello I; Farias J; G-Millet V
Transplant Proc; 1992 Feb; 24(1):35-6. PubMed ID: 1539312
[No Abstract] [Full Text] [Related]
8. OKT3 prophylaxis in liver transplant patients: a European and Australian multicenter, prospective controlled trial.
Höckerstedt K; Ericzon BG; Bismuth H; Chapuis Y; Farges O; Faure JL; Galmarini D; Houssin D; Lynch SV; Miguet J
Transplant Proc; 1993 Feb; 25(1 Pt 1):556-7. PubMed ID: 8438412
[No Abstract] [Full Text] [Related]
9. Cyclosporine vs OKT3 prophylaxis after orthotopic liver transplantation.
Pons JA; Bueno F; Parrilla P; Ramirez P; Bixquert V; Robles R; Miras M; Rodriguez J
Transplant Proc; 1993 Apr; 25(2):1949. PubMed ID: 8470238
[No Abstract] [Full Text] [Related]
10. Delayed graft function is associated with an increased incidence of occult rejection and results in poorer graft survival.
Howard RJ; Pfaff WW; Brunson ME; Ramos EL; Peterson JC; Croker BP; Scornik JC; Parris CJ; Fennell RS
Transplant Proc; 1993 Feb; 25(1 Pt 2):884. PubMed ID: 8442256
[No Abstract] [Full Text] [Related]
11. Monitoring of donor sensitization in kidney transplant recipients by flow cytometric crossmatch.
Cinti P; Bachetoni A; Baiano V; Pretagostini R; Poli L; Berloco P; Renna Molajoni E; Cortesini R
Transplant Proc; 1993 Dec; 25(6):3265-6. PubMed ID: 8266536
[No Abstract] [Full Text] [Related]
12. Prophylactic OKT3, CyA, and steroids versus antilymphoblast globulin, CyA, and steroids in cadaveric kidney transplantation.
Griñó JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Bover J; Torras J; Alsina J
Transplant Proc; 1992 Feb; 24(1):39-41. PubMed ID: 1539329
[No Abstract] [Full Text] [Related]
13. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI
Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
[No Abstract] [Full Text] [Related]
14. Low incidence of chronic rejection in patients experiencing histological acute rejection without simultaneous impairment in liver function tests.
Farges O; Nocci Kalil A; Sebagh M; Reynes M; Bismuth H
Transplant Proc; 1995 Feb; 27(1):1142-3. PubMed ID: 7878827
[No Abstract] [Full Text] [Related]
15. FK 506 treatment of intractable rejection after liver transplantation.
Jost U; Winkler M; Ringe B; Rodeck B; Pichlmayr R
Transplant Proc; 1993 Aug; 25(4):2686-7. PubMed ID: 7689276
[No Abstract] [Full Text] [Related]
16. FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease.
Woodle ES; Perdrizet GA; So S; Jendrisak MD; White HM; Marsh JW
Transplant Proc; 1993 Apr; 25(2):1992-3. PubMed ID: 7682360
[No Abstract] [Full Text] [Related]
17. Low-dose OKT3 induction therapy following renal transplantation leads to improved graft function and decreased adverse effects.
Brown M; Korb S; Light JA; Light T; Jonsson J; Aquino A
Transplant Proc; 1993 Feb; 25(1 Pt 1):553-5. PubMed ID: 8438411
[No Abstract] [Full Text] [Related]
18. Effect of subclinical rejection on renal allograft histology and function at 6 months.
Rush D; Jeffery J; Trpkov K; Solez K; Gough J
Transplant Proc; 1996 Feb; 28(1):494-5. PubMed ID: 8644325
[No Abstract] [Full Text] [Related]
19. Induction therapy with OKT3 in pediatric liver-transplant recipients.
Ryckman FC; Schroeder TJ; Pedersen SH; Dittrich VS; Balistreri WF
Transplant Sci; 1994 Dec; 4 Suppl 1():S20-5. PubMed ID: 7627451
[TBL] [Abstract][Full Text] [Related]
20. OKT3 vs FK 506 rescue management of acute steroid-resistant and chronic rejection.
Platz KP; Mueller AR; Zytowski M; Bechstein WO; Blumhardt G; Lobeck H; Neuhaus P
Transplant Proc; 1995 Feb; 27(1):1111-3. PubMed ID: 7533357
[No Abstract] [Full Text] [Related]
[Next] [New Search]
